An FDA panel is urging Acrotech Biopharma to accelerate research into the efficacy of two blood cancer drugs brought to market via the agency’s accelerated approval pathway.
Read the full post on Becker's Hospital Review - Healthcare News
FDA eyes efficacy of $900K cancer drug
